About Metabolon, Inc.
Metabolon, Inc. has invested more than 20 years into building the best metabolomic competency in the world to reveal biological insights otherwise unseen. Today, Metabolon enables, accelerates, and supports drug development through biomarker discovery, understanding the mechanism of action, patient stratification, and more, as evidenced by >3,000 citations, numerous high-impact publications, case studies, and customer testimonials.  

Metabolomics can instantaneously provide a snapshot of the entire physiology of a living being by studying the metabolites or the small-molecule end products of metabolism. The resulting full picture of a biological system enables a deep understanding of health, disease, and treatment response, whether influenced by genes, the environment, epigenetics, or the microbiome.  

Metabolon’s 4Cs approach sets the standard of performance across Coverage, Competency, Comparability, and Capacity for the most complete biological insights into disease state and physiological reactions in the present time. The company’s technology provides the fullest view of the metabolome to detect and identify metabolites with the highest fidelity. Metabolon has the world’s most extensive reference library of compounds that currently includes 5,400+ total known molecules, enabling the ability to compare thousands of molecules to reveal new insights and opportunities across diverse markets. 

Metabolon offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. Metabolon is equipped to deliver biologically relevant insights to address some of the most challenging and pressing questions in the life sciences. Metabolon is ISO 9001:2015 certified for analytical and diagnostic testing of biological specimens, certified by Clinical Laboratory Improvement Amendments of 1988 (CLIA), and accredited by the College of American Pathologists (CAP) for diagnostic testing on human specimens.

The company, founded in 2000, is based in Research Triangle Park, North Carolina.

What is Metabolomics?

Metabolomics, the study of metabolites, the small-molecule end products of metabolism collectively known as the metabolome, provides the full picture of a biological system enabling a deep understanding of health, disease, and treatment response, whether influenced by genes, the environment, epigenetics, or the microbiome.

Metabolon’s proprietary untargeted metabolomics platform reveals biological insights otherwise unseen. Metabolon sets the standard in metabolomics and accelerates research and product development in every sector from pharma and agriculture to consumer products and wellness, as well as population health and academia.

Why Metabolon?

Metabolon’s approach sets the standard of 4Cs for performance: Coverage, Competency, Comparability and Capacity for the most complete picture. The unmatched depth provides functional metabolite understanding, fuelling deep insights and enabling our clients to accelerate research and product development success in the pharma, population health, consumer products, agriculture, wellness, and academic research sectors.

Metabolon offers a range of metabolomics service offerings that support and advance research at every stage. Wherever you are in your research and development journey, our team of experts will work with you to clearly define your goals and develop a customized plan to meet them.

We offer applications throughout the drug discovery and preclinical development continuum and product lifecycle:

Discovery – Target Selection
Novel biomarkers
Disease taxonomy
Target discovery
Target selection
Mechanism of action
Inherent translatability

Lead – Candidate Selection
Lead optimization
Early toxicological and secondary effects
Candidate selection

Preclinical
Efficacy biomarkers
PD biomarkers
Off-target effect characterization

Clinical
Clinical Responders vs non-responders
Patient stratification
Efficacy signals
Prodromal safety signals
Lifecycle Management
Blackbox warning mitigation
Real-world evidence
New indication identification
Off-target effects
Bioprocessing optimization